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BACKGROUND Cangrelor, an intravenous, rapidly acting P2Y12 in-
hibitor, is superior to clopidogrel in reducing ischemic events in PCI
patients with stable ischemic heart disease and acute coronary syn-
dromes. We examined the safety and efﬁcacy of cangrelor in relation
to the extent of coronary artery disease.
METHODS We studied a prespeciﬁed modiﬁed intention to treat
population of patients with single vessel and multivessel coronary
disease. The primary efﬁcacy outcome was the composite of death,
myocardial infarction (MI), ischemia-driven revascularization (IDR),
and stent thrombosis (ST) at 48 hours. Kaplan Meier analysis of the
primary outcome was performed through 30 days. The safety outcome
was non-CABG GUSTO severe bleeding at 48 hours.
RESULTS Among 10,921 patients, 5,296 (48%) had single vessel disease
(SVD) and 5,625 (52%) had multivessel disease (MVD). Patients with MVD
were older (65 vs. 63 years), less often female (25% vs. 31%), andmore often
had diabetes (31% vs. 25%), hypertension (82% vs. 77%), and prior MI (25%
vs. 16%). At 48 hours, MVD patients had higher rates of death/MI/IDR/ST
(6.3% v 4.2%, p¼<0.001), but not GUSTO severe bleeding (0.1% vs. 0.2%,
p¼0.71) compared with SVD patients. Consistent with outcomes in the
overall population, cangrelor resulted in fewer death/MI/IDR/ST events
comparedwith clopidogrel in patientswith SVD (3.9% v 4.5%; OR0.88, 95%
CI 0.67-1.15) and with MVD (5.4% vs. 7.3%; OR 0.73, 95% CI 0.59-0.91), p-
interaction¼0.31. 30-day Kaplan-Meier estimates of death/MI/IDR/ST are
shown in Figure 1. Bleeding rates were not different between cangrelor andclopidogrel in either SVD orMVD patients (SVD: OR 3.04; 95% CI 0.61-15.06;
MVD: OR 0.74; 95% CI 0.17-3.32; p-interaction 0.21).
CONCLUSIONS Patients with MVD compared to SVD had higher risk
of ischemic complications after PCI but not severe bleeding. Cangrelor
reduced ischemic complications compared with clopidogrel with
consistent reductions in higher risk MVD patients and lower risk SVD
patients with no signiﬁcant increase in severe bleeding.
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BACKGROUND Optimal duration of dual antiplatelet therapy (DAPT)
after percutaneous coronary intervention (PCI) for complex coronary
lesions and patients is still controversial. There is no randomized
study investigating shorter (6 months) vs. standard (12 months)
duration of DAPT after PCI for bifurcation lesions. We sought to report
the 18-month results of the bifurcation substudy from the I-LOVE-IT 2
trial, which compared safety and efﬁcacy between patients receiving
6- vs. 12-month DAPT after implantation of a novel biodegradable
polymer sirolimus-eluting stent (BP-SES).
METHODS In the prospective randomized I-LOVE-IT 2 trial, 1829 pa-
tients who were allocated to the BP-SES group were also randomized to
receive either 6-month (n¼909) or 12-month DAPT (n¼920) pre-stent-
ing; among them there were 717 patients (349 in 6-month DAPT group
and 368 in 12-month DAPT group, respectively) with bifurcation le-
sions. The major endpoints were target lesion failure (TLF, a composite
of cardiac death, target vessel myocardial infarction [TV-MI], or clini-
cally indicated target lesion revascularization [CI-TLR]) and net
adverse clinical and cerebral events (NACCE, a composite of all-cause
death, all MI, stroke, or major bleeding [Bleeding Academic Research
Consortium  type 3]) at 18 months. Landmark analyses at 6 months
were used to derive event rates between 6 and 18 months of follow-up.
RESULTS The demographic, lesion or procedural characteristics were
similar between groups. Eighteen-month TLF rate was numerically
higher in the 6-month DAPT group compared to the 12-month DAPT
group (9.3% vs. 5.5%, p¼0.055), which was mainly driven by an
increased CI-TLR between 6 and 18 months (3.5% vs. 1.1%, p¼0.03) in
the 6-month DAPT group when patients have discontinued DAPT.
There were no signiﬁcant differences in NACCE, death, MI, stroke, and
stent thrombosis (ST) at 18 months or between 6 and 18 months period
of follow-up. However, there was a non-signiﬁcant tendency of lower
all bleeding events in favoring 6-month DAPT strategy according to
the landmark analysis (1.2% vs. 3.3%, p¼0.056). Major clinical out-
comes were shown in table.
Table. Major Clinical Outcomes0-18 Months 6-18 Months (Landmark)6-month
DAPT Group
n [ 34912-month
DAPT Group
n [ 368 P6-month
DAPT Group
n [ 34712-month
DAPT Group
n [ 367 PTLF 9.3 (32) 5.5 (20) 0.055 4.0 (14) 1.6 (6) 0.052NACCE 8.7 (30) 6.6 (24) 0.30 2.6 (9) 3.0 (11) 0.74All-cause Death 2.0 (7) 1.7 (6) 0.71 1.4 (5) 1.4 (5) 1.00Cardiac Death 1.2 (4) 0.8 (3) 0.72 0.6 (2) 0.5 (2) 1.00All MI 5.8 (20) 4.1 (15) 0.31 1.2 (4) 0.5 (2) 0.44TV-MI 4.9 (17) 3.0 (11) 0.20 0.9 (3) 0.3 (1) 0.36Stroke 2.0 (7) 1.7 (6) 0.71 1.2 (4) 1.4 (5) 1.00Any
Revascularization6.1 (21) 5.5 (20) 0.74 4.9 (17) 3.3 (12) 0.27TVR 4.4 (15) 3.0 (11) 0.35 3.5 (12) 1.4 (5) 0.07CI-TLR 4.4 (15) 2.5 (9) 0.17 3.5 (12) 1.1 (4) 0.03All Bleeding 4.1 (14) 6.1 (22) 0.23 1.2 (4) 3.3 (12) 0.056Major Bleeding 0.3 (1) 0.6 (2) 1.00 0.3 (1) 0.3 (1) 1.00Deﬁnite/Probable
ST0.6 (2) 0.3 (1) 0.62 0 0 -CONCLUSIONS The present study indicates that 6 months of DAPT
might be insufﬁcient in patients after PCI (even with novel BP-SES) for
